Pacer WealthShield ETF
Limited financial coverage for PWS.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
Pacer Funds Trust - Pacer WealthShield ETF is an exchange traded fund launched and managed by Pacer Advisors, Inc. The fund invests in public equity and fixed income markets of the United States. It invests directly and through other funds to create its portfolio.
- IPO
- 2017
- HQ
- Malvern, PA, US
Get TickerSpark's AI analysis on PWS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $25.11M
- Div Yield
- 1.26%
- 52W High
- $33.83
- 52W Low
- $30.85
- 50D MA
- $32.58
- 200D MA
- $32.55
- Beta
- 0.72
- RSI (14)
- 62
- Avg Volume
- 3.25K
No earnings-call transcripts are available for PWS yet.
- Free Float
- 0.0%
- Shares Outstanding
- 750.01K
- Float Shares
- 0
of shares held by institutions
17 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Napa Wealth Management | 294.18K | ▲ 108.83K |
| Org Partners LLC | 42.98K | ▼ 321 |
Our PWS coverage
Recent articles, reports, and earnings notes.
No research on PWS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PWS report →AARD SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Aardvark (AARD) Investors of Securities Class Action Lawsuit Deadline on October 13, 2026
gurufocus.com · Aug 16
ConSynance Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of CSTI-500 for Prader-Willi Syndrome
globenewswire.com · Jun 16
Soleno Therapeutics Presents New VYKAT® XR (diazoxide choline) Data at ENDO 2026 Demonstrating Meaningful and Durable Improvements in Hyperphagia and Behavioral Symptoms in Prader-Willi Syndrome Following Randomized Withdrawal Period
prnewswire.com · Jun 15
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
globenewswire.com · Jun 13
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
globenewswire.com · Jun 12
Neurocrine Biosciences to Present New Two‑Year CRENESSITY® (crinecerfont) Data on Key Clinical and Patient‑Reported Outcome Measures at ENDO 2026
gurufocus.com · Jun 3
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.